Conference Details - Exhibitors

Abraxis BioScience

45

Abraxis Oncology is the proprietary pharmaceuticals division of Abraxis BioScience, a fully integrated global biotechnology company. Abraxis Oncology is dedicated to the discovery and development of novel cancer therapies that target tumor biologic pathways.

Agendia

28

Agendia’s MammaPrint^® is the first and only FDA-cleared IVDMIA gene-expression assay for assessing breast cancer recurrence risk. The 70-gene signature, which was developed in an untreated patient population using an unbiased gene selection process, provides clinicians with a reliable means of identifying women who are at either low or high risk of relapse after surgery. Submitting patient samples in the United States is simple and easy using the RNARetain™ ambient temperature, molecular-fixation protocol as outlined in the 2007 National Cancer Institute recommendations. Agendia is based in Huntington Beach, CA, and Amsterdam, The Netherlands. For more information, please visit www.agendia.com.

Alliance Imaging, Inc.

T10

Alliance Imaging, Inc., is a leading national provider of outpatient diagnostic imaging and radiation therapy services, with > 1000 customers in 46 states. Alliance provides comprehensive management and turnkey design/build solutions for MRI, PET/CT, CT, radiation therapy, and stereotactic radiosurgery as well as shared mobile services to hospitals, breast health centers, and other health care providers.

Aptium Oncology

T3

Aptium Oncology has 25 years of experience in planning, developing, and managing hospital-based oncology centers, with a steadfast vision of helping patients with cancer live longer, better lives. The Aptium network includes affiliations with leading academic and community hospitals, including NYU Langone Medical Center, Cedars-Sinai Medical Center, Alta Bates Summit Medical Center, Desert Regional Medical Center, Mount Sinai Medical Center, Boca Raton Community Hospital, Trinitas Hospital, and St. Vincent’s Hospital (New York).

Bard Biopsy Systems

55

Bard’s VACORA^® vacuum-assisted breast biopsy system enables physicians to perform a minimally invasive breast biopsy while obtaining large, high-quality, contiguous tissue samples for use with ultrasound, stereotactic x-ray, and MR image guidance. The VACORA biopsy device eliminates the need for external vacuum carts and tubing, generators, wires, and foot pedals. VACORA is engineered for exceptional handheld control and ease of use. VACORA probes are available in convenient 10- and 14-gauge sizes. Bard also offers breast tissue markers and localization wires; core needle biopsy systems for lung, liver, breast, and prostate biopsies; and the Navarre drainage catheter.

Biopsy Sciences

T11

Biopsy Sciences introduces HydroMARK^®. It’s the only breast tissue marker that is made of 90% water, has < 2 mm of migration, marks the exact biopsy location, and does not contain collagen (which has known allergies). Because it’s 90% water, HydroMARK enables physicians to clearly visualize the marker under ultrasound for ? 6 weeks. For more information, please visit www.hydromark.com.

Bristol-Myers Squibb

46

Bristol-Myers Squibb welcomes you to Miami. We invite you to visit our exhibit and learn about the products and services that Bristol-Myers Squibb has to offer for your specialty.

Carl Zeiss, Inc.

4

The Zeiss INTRABEAM^® System offers the least disruptive treatment method available to patients being treated for early-stage breast cancer. The radiation dose is administered to the tumor bed in the operating room following lumpectomy. This system utilizes the miniature X-ray source, a highly stable support stand, and a full range of applicator options. The INTRABEAM System is simple, convenient, and reliable.

Centocor Ortho Biotech, Inc.

44

Cianna Medical, Inc.

T1

Cianna Medical, Inc., manufactures and markets the SAVI™ breast brachytherapy applicator, which allows physicians to selectively radiate the tissue at greatest risk for recurrence while reducing exposure of healthy tissue. The ability to customize the radiation dose allows physicians to treat patients who otherwise would have been eliminated as candidates for APBI.

CURE Media Group

T14

TBA

Dilon Technologies

35

The Dilon 6800 Gamma Camera, Dilon’s cornerstone product, is a high-resolution, small field-of-view gamma camera optimized to perform breast-specific gamma imaging, a molecular breast-imaging procedure that aids in the effective management of suspicious and difficult-to-interpret breast cases. The Dilon 6800 captures vital information by viewing the metabolic activity in the breast; it can identify lesions independent of tissue density and is capable of duplicating standard mammographic views.

DxS Limited

29

DxS Limited is a personalized medicine company providing molecular diagnostics to aid doctors and drug companies in selecting therapies for patients. DxS works in partnership with pharmaceutical companies to support the development and sales of targeted cancer therapies by providing biomarkers and companion diagnostics. The DxS real-time PCR products include assays for detecting mutations in KRAS, EGFR, BRAF, P13K, and BCR-ABL oncogenes. For further information, please visit www.dxsdiagnostics.com.

Elsevier, Inc.

T9

Elsevier, Inc., is the leading international publisher of medical journals, books, and electronic products.

Ethicon Endo-Surgery, Inc.

40

Ethicon Endo-Surgery, Inc., features the Mammotome^® System, a minimally invasive biopsy device used for partial or selective removal of imaged evidence of both palpable and nonpalpable breast lesions. Harmonic^® represents a robust line of ultrasonic surgical devices from Ethicon Endo-Surgery designed for both laparoscopic and open procedures. These devices offer simultaneous cutting and coagulation as well as minimal lateral thermal damage to tissue compared to electrosurgery devices.

Faxitron X-Ray LLC

T2

Faxitron X-Ray LLC is introducing a new digital core-specimen radiography system. Named the DX-50 Core™, the unit features a new, smaller camera and is intended for dedicated use in the stereotactic suite. The compact unit produces high-resolution digital images in seconds that can be viewed immediately on its flat-panel display to ensure that core specimens contain a representative sample of microcalcifications. For more information, contact Brad Jackson, VP Sales and Marketing, Faxitron X-Ray LLC, 575 Bond St, Lincolnshire, IL 60069; call 1-847-276-3427; or visit www.faxitron.com.

Florida Breast Cancer Coalition

T8

The mission of the Florida Breast Cancer Coalition Research Foundation is to end breast cancer through advocacy, education, and research. All funds generated by FBCCRF stay in the state of Florida. We are the only organization in the state of Florida with the “End of Breast Cancer” license plate, the proceeds from which help us to fund scientific research and educational programs throughout Florida.

Gamma Surgery, Inc.

T6

Gamma Surgery, Inc., provides complete gamma probe surgical service for the busy surgeon and is the premiere provider of radioguided surgery for breast cancer, melanoma, and parathyroid adenoma. Gamma Surgery, Inc., is celebrating our 15th year of professional service!

Genentech BioOncology

63

At Genentech BioOncology, we’re fundamentally transforming the way cancer is treated, with the goal of moving cancer toward a more manageable disease. Our research efforts are conducted by scientists dedicated to defining the molecular basis of cancer and investigating multiple approaches to treating the disease.

Genomic Health

5

Genomic Health, Inc., a life science company located in Redwood City, CA, conducts sophisticated genomic research to develop clinically validated molecular diagnostics that provide individualized information on the likelihood of disease recurrence and response to certain types of therapy. These diagnostic technologies generate information that physicians and patients can use in making treatment decisions.

GlaxoSmithKline

34

GlaxoSmithKline is a leading research-based pharmaceutical company with a powerful combination of skills to discover and deliver innovative medicines. We offer a number of programs to support effective health-management strategies and improve patient care. Please visit our exhibit to learn more about our products.

Hologic, Inc.

23

Hologic, Inc., is leading the way in women’s imaging and intervention technology. Our technologies provide clinicians with fast, effective, and accurate biopsy solutions. Our systems are designed for use across all 3 imaging modalities: stereotactic, ultrasound, and MRI. We also support your patients with a breakthrough treatment option, MammoSite^®, a 5-day targeted radiation therapy. Learn more about our comprehensive intervention and treatment solutions by visiting our exhibit at the Miami Breast Cancer Conference or by visiting www.hologic.com.

ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company

57

ImClone Systems is dedicated to developing and commercializing novel therapeutic products in the field of oncology. Our efforts have resulted in a commercially available novel therapy, Erbitux^® (cetuximab), as well as a broad spectrum of innovative product candidates with potential application in multiple tumor types. As a member of the oncology community, we are committed to providing treatments to meet the unmet needs of patients with cancer.

ImpediMed

3

Protect your patient’s quality of life. Prospectively manage lymphedema after breast cancer treatment. FDA-cleared, clinically validated technology detects specifically extracellular fluid and compliments the new National Institutes of Health paradigm of presurgical baseline and postsurgical surveillance, enabling early identification and treatment using conservative cost-effective measures. Detect subclinical changes before visible swelling. ImpediMed provides the rapid, objective, standardized L-Dex™ device with tracking software.

Intact Medical Corp.

27

Intact Medical’s Breast Lesion Excision System (BLES) can remove an intact breast lesion, preserving spatial relationship and architecture so that margins and extent can be fully evaluated. The company will also be showing the Excise XL.

IntraOp Medical

10

IntraOp Medical and its flagship product, the Mobetron, provide innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools that doctors need to administer radiation safely and effectively to all patients with cancer.

Kubtec

T4

Kubtec offers digital specimen x-ray systems for surgically excised tissue and stereotactic core biopsies. We offer systems that are compact in size and equipped with zero warm-up time, user-friendly software, automatic exposure control, autocalibration, automatic window leveling, and the ability to send multiple images with annotations to PACS (also available through Hologic, Inc., and Siemens Corporation).

Lilly USA, LLC

8 and 9

Lilly Oncology, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and collaborations with eminent scientific organizations. Headquartered in Indianapolis, IN, Lilly provides answers for some of the world’s most urgent medical needs through medicines and information.

Lippincott Williams & Wilkins

T7

Lippincott Williams & Wilkins is one of the leaders in oncology text and journal publishing. We will be displaying several new titles at this year’s meeting and hope to get a chance to meet with everyone to explain our products.

Monogram Biosciences, Inc.

T15

Always the pioneer in individualized medicine, Monogram Biosciences, Inc., continues to grow into new areas of health care diagnostics. Our broadly applicable VeraTag™ oncology assays are designed to help physicians better determine whether certain therapies are appropriate for individual patients with cancer and whether to combine therapies.

Monogram’s HERmark™ Breast Cancer Assay, based on our VeraTag technology, has been validated as an accurate, precise, reproducible assay measuring the levels of HER2 total protein and HER2 homodimers. With more accurate and quantitative results than HER2 status, HERmark allows physicians to make more optimal therapeutic decisions when defining the best course of treatment for patients with breast cancer.

Myriad Genetic Laboratories

26

Myriad Genetic Laboratories develops and markets predictive and pharmacogenetic testing products, including the BRACAnalysis^® family of sequence analysis services for genetic susceptibility to breast and ovarian cancer and a diagnostic test that can assess a patient’s risk of developing toxicity to 5-fluorouracil–based chemotherapeutics.

National Accreditation Program for Breast Centers (NAPBC)

T12

The National Accreditation Program for Breast Centers is a consortium of national professional organizations dedicated to the improvement of the quality of care and monitoring of outcomes for patients with diseases of the breast. This multidisciplinary group defined 27 program standards and 17 program components of care that collectively define the most efficient and contemporary care available.

Novartis Oncology

1

Novartis Oncology delivers a broad range of innovative therapies to potentially improve and extend the lives of patients. These include Gleevec^® (imatinib mesylate), Exjade^® (deferasirox), Zometa^® (zoledronic acid), Sandostatin LAR^® depot (octreotide acetate for injectable suspension), and Femara^® (letrozole tablets). Novartis Oncology has a robust pipeline capitalizing on recent discoveries in molecular genomics, rational drug design, and state-of-the-art drug discovery technologies.

Pfizer Oncology

53 and 54

Please visit the Pfizer Inc. US Pharmaceuticals exhibit featuring Aromasin^® (exemestane).

ProStrakan, Inc.

58

ProStrakan, Inc., is one of Europe’s fastest growing pharmaceutical companies, with new headquarters in Bedminster, NJ. Our primary inspiration is developing innovative medicines to improve the lives of patients, with a focus on treating unmet needs. SANCUSO^® (Granisetron Transdermal System), the first and only patch indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens for up to 5 consecutive day, is our first product to receive US FDA approval. For more information, please visit www.ProStrakan-USA.com and www.sancuso.com.

sanofi-aventis U.S.

43

The sanofi-aventis group is the world’s third-largest pharmaceutical company, ranking number 1 in Europe. Backed by a world-class research and development organization, sanofi-aventis is developing leading positions in 7 major therapeutic areas: cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal medicine, and vaccines.

Toshiba American Medical Systems

7

SMI Ultrasound, the only authorized distributor for both Toshiba and MindRay ultrasounds to surgeons in the United States, is now showcasing the latest in hand-carried, color Doppler ultrasound systems, perfect for both the office and the operating room: the M5. Our cart-based color Doppler ultrasound, the Nemio XG, provides radiologic quality scans at an affordable, office-based price. Both ultrasound systems will be available for hands-on demonstrations at our booth. For over 15 years, we at SMI Ultrasound have prided ourselves on our commitment to excellence with the products we offer and the customer service we provide.

Vector Surgical

T5

Vector Surgical’s devices set the new standard for tissue orientation. MarginMarker^® is a sterile ink kit that the surgeon uses in the operating room to clearly delineate the margins of excised tissue. Pathologists receive a more precise orientation, improving the accuracy of re-excisions and reducing cancer recurrence. CorrectClips^® are lettered radiographic clips that directly and securely grip excised tissue for orientation on the image. Both MarginMarker and CorrectClips increase accuracy and safety while saving valuable operating room time.